CDC: Moderna vaccine most effective against hospitalization in U.S.

·1 min read

Overall healthy adults with the Moderna COVID vaccine had 93% vaccine effectiveness against hospitalization over five months compared to those with 88% protection with Pfizer and 71% from the Johnson & Johnson vaccine, a new report out Friday from the CDC shows.

Why it matters: The report comes as the Food and Drug Administrations meets Friday to consider whether to endorse a contentious plan for booster shots among the fully vaccinated.

Get market news worthy of your time with Axios Markets. Subscribe for free.

  • The higher effectiveness of Moderna could be due to the higher mRNA content or the difference between the timing between doses, the authors note.

  • Still, all three vaccines provided “substantial protection," the CDC says, despite both mRNA vaccines providing "more protection” than the J&J shot.

The big picture: The real-world data coincides with previous findings of how Moderna may maintain higher effectiveness over time than the other shots available in the United States.

  • The waning effectiveness in Pfizer may raise future questions about whether the two mRNA vaccines should be treated the same way policy-wise, Axios' Caitlin Owens reports.

By the numbers: The sample size was from nearly 3,700 people at 21 hospitals in 18 states from March 11 to Aug. 15. Patients with immunocompromising conditions were excluded from the report.

  • About 13% were fully vaccinated with Moderna, 20% were fully vaccinated with Pfizer and 3.1% had J&J.

  • Vaccine effectiveness for those 14-120 days after the second dose of Moderna was 93% and dropped to 92% after about four months, the data show.

What they're saying: "Understanding differences in [vaccine effectiveness] by vaccine product can guide individual choices and policy recommendations regarding vaccine boosters," the study's authors wrote.

  • "All FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization," they added.

Like this article? Get more from Axios and subscribe to Axios Markets for free.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting